KNOXVILLE, Tenn., Jan. 17 /PRNewswire-FirstCall/ -- Provectus Pharmaceuticals, Inc. announced today it has received the Company’s thirteenth U.S. patent (U.S. Patent 6,986,740), which is its third U.S. patent for its pharmaceutical products.
The patent covers use of the Company’s anti-cancer pharmaceutical agent Provecta(TM) in conjunction with ultrasound imaging, augmenting earlier patents for use of the agent for cancer treatment and CT and MRI imaging. Provecta is a small-molecule, tumor-specific agent currently in clinical trials for treatment of metastatic melanoma and breast cancer.
“This patented technology provides a convenient means for monitoring drug delivery during treatment,” noted Craig Dees, Ph.D., Provectus CEO and co- inventor. “Together with CT and MRI imaging, we have shown that the distribution of Provecta can be viewed using the most common medical imaging modalities, facilitating precise treatment of cancerous tumors.”
About Provectus Pharmaceuticals, Inc.
Provectus Pharmaceuticals, Inc. is a pioneering pharmaceutical company actively engaged in the design, development and marketing of pharmaceutical technologies for the treatment of metastatic melanoma, breast cancer and liver cancer. In addition, Provectus is preparing to begin Phase 2 clinical studies for the Company’s topical agent Xantryl(TM), a treatment for psoriasis.
The Company’s offices and laboratory are located at 7327 Oak Ridge Highway, Suite A, Knoxville, TN 37931; telephone: 865 769 4011.
For more information, contact the Company at info@pvct.com or visit the corporate Web site: http://www.pvct.com .
This release and others statements issued or made from time to time by the company or its representatives contain comments that may constitute forward- looking statements. Those include statements regarding the intent, belief or current expectations of the company and members of its management teams, as well as the assumptions on which the statements are based. Prospective investors are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward- looking statements.
Provectus Pharmaceuticals, Inc.
CONTACT: Peter Culpepper, Provectus Pharmaceuticals, Inc.,+1-865-769-4011, or culpepper@pvct.com; or investors, Matt Clawson of Allen& Caron Inc., +1-212-691-8087, or matt@allencaron.com, for Provectus
Web site: http://www.pvct.com/